Previous studies have revealed that different factors, such as the patient’s age at first breast cancer diagnosis, the type of pathogenic variant (ie, BRCA1 or BRCA2), first breast cancer subtype, adjuvant systemic treatment received, presence or absence of ovarian cancer, may influence the degree to which a particular patient will benefit from various prophylactic strategies [15,16,22-33]. This evidence concerns the gene BRCA1 and breast carcinoma.